These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 8289971)
1. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation. Macková NO; Fedorocko P Neoplasma; 1993; 40(6):379-85. PubMed ID: 8289971 [TBL] [Abstract][Full Text] [Related]
2. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse. Fedorocko P Int J Radiat Biol; 1994 Apr; 65(4):465-75. PubMed ID: 7908934 [TBL] [Abstract][Full Text] [Related]
3. Effect of liposomal muramyl tripeptide phosphatidylethanolamine and indomethacin on hematopoietic recovery in irradiated mice. Macková NO; Fedorocko P Physiol Res; 2002; 51(5):511-21. PubMed ID: 12470204 [TBL] [Abstract][Full Text] [Related]
4. Combined modality radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin. Fedorocko P; Macková NO Int J Immunopharmacol; 1996 May; 18(5):329-37. PubMed ID: 8933212 [TBL] [Abstract][Full Text] [Related]
5. Influence of liposomal muramyl tripeptide phosphatidylethanolamine on the changes of nucleic acids in the blood and hemopoietic tissues of irradiated mice. Misúrová E; Fedorocko P Neoplasma; 1995; 42(2):63-8. PubMed ID: 7542365 [TBL] [Abstract][Full Text] [Related]
6. Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents. Killion JJ; Kleinerman ES; Wilson MR; Tanaka M; Fidler IJ Oncol Res; 1992; 4(10):413-8. PubMed ID: 1292756 [TBL] [Abstract][Full Text] [Related]
7. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. Fidler IJ; Fogler WE; Brownbill AF; Schumann G J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979 [TBL] [Abstract][Full Text] [Related]
8. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249 [TBL] [Abstract][Full Text] [Related]
9. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide. Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921 [TBL] [Abstract][Full Text] [Related]
11. Treatment of experimental lung metastasis with local thoracic irradiation followed by systemic macrophage activation with liposomes containing muramyl tripeptide. Saiki I; Milas L; Hunter N; Fidler IJ Cancer Res; 1986 Oct; 46(10):4966-70. PubMed ID: 3756858 [TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Kleinerman ES; Maeda M; Jaffe N Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724 [TBL] [Abstract][Full Text] [Related]
13. [L-MTP-PE--a potential antineoplastic agent]. Dzierzbicka K; Gozdowska M; Kołodziejczyk AM Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567 [TBL] [Abstract][Full Text] [Related]
14. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. Verweij J; Judson I; Steward W; Coleman R; Woll P; van Pottelsberghe C; van Glabbeke M; Mouridsen H Eur J Cancer; 1994; 30A(6):842-3. PubMed ID: 7917546 [TBL] [Abstract][Full Text] [Related]
16. Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities. Fedorocko P; Hoferová Z; Hofer M; Brezáni P Neoplasma; 2003; 50(3):176-84. PubMed ID: 12937850 [TBL] [Abstract][Full Text] [Related]
18. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes. Fogler WE; Fidler IJ Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507 [TBL] [Abstract][Full Text] [Related]
19. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats. Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380 [TBL] [Abstract][Full Text] [Related]
20. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro. Maeda M; Knowles RD; Kleinerman ES Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]